SCHEMBL1310429

SCHEMBL1310429

Clc1nc(Cl)nc(NCc2ccccn2)n1

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAOA P21397 3/20 0.58
MAOB P27338 3/20 0.58
JAK2 O60674 1/20 0.52
IGF1R P08069 1/20 0.52
PIM1 P11309 1/20 0.52
SRC P12931 1/20 0.52
CSNK2A2 P19784 1/20 0.52
KCNA5 P22460 1/20 0.52
JAK1 P23458 1/20 0.52
CCNE1 P24864 1/20 0.52
CDK2 P24941 1/20 0.52
TYK2 P29597 1/20 0.52
FLT4 P35916 1/20 0.52
FLT3 P36888 1/20 0.52
MAP3K8 P41279 1/20 0.52
CSNK1A1 P48729 1/20 0.52
GSK3B P49841 1/20 0.52
JAK3 P52333 1/20 0.52
PLK1 P53350 1/20 0.52
CSNK2A1 P68400 1/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24054791 0.89 LMNA (0.58) MAOAMAOBJAK2IGF1RPIM1
SCHEMBL1310511 0.85 CYP1A2 (0.58) PIM1SMN1; SMN2KDM4ENPC1RAB9A
SCHEMBL3556495 0.84 MAOA (0.56) MAOAMAOBJAK2IGF1RPIM1
SCHEMBL1244338 0.81 MAOA (0.70) MAOAMAOBSMN1; SMN2KDM4EHPGD
SCHEMBL23431636 0.80 IDH1 (0.46) MAOAMAOBJAK2IGF1RPIM1
SCHEMBL3976219 0.79 MAOA (0.54) MAOAMAOBJAK2IGF1RPIM1
SCHEMBL3560364 0.79 KDM4E (0.53) MAOAMAOBJAK2IGF1RPIM1
SCHEMBL1309502 0.79 HTT (0.56) SMN1; SMN2KDM4EHTTALDH1A1MEN1
SCHEMBL27609444 0.79 MAOA (0.60) MAOAMAOBSMN1; SMN2KDM4EHPGD
SCHEMBL4290043 0.79 MAOA (0.58) MAOAMAOBSMN1; SMN2KDM4EHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8921361-B2 Triazine, pyrimidine and pyridine analogs and their use as therapeutic agents and diagnostic probes UNIVERSITY OF BASEL (CH) 2014-12-30 US disclosed
US-8921361-B2 Triazine, pyrimidine and pyridine analogs and their use as therapeutic agents and diagnostic probes UNIVERSITY OF BASEL (CH) 2014-12-30 US disclosed
US-8921361-B2 Triazine, pyrimidine and pyridine analogs and their use as therapeutic agents and diagnostic probes UNIVERSITY OF BASEL (CH) 2014-12-30 US disclosed
US-20110275762-A1 TRIAZINE, PYRIMIDINE AND PYRIDINE ANALOGS AND THEIR USE AS THERAPEUTIC AGENTS AND DIAGNOSTIC PROBES UNIVERSITY OF BASEL (CH) 2011-11-10 US disclosed
US-20110275762-A1 TRIAZINE, PYRIMIDINE AND PYRIDINE ANALOGS AND THEIR USE AS THERAPEUTIC AGENTS AND DIAGNOSTIC PROBES UNIVERSITY OF BASEL (CH) 2011-11-10 US disclosed
US-20110275762-A1 TRIAZINE, PYRIMIDINE AND PYRIDINE ANALOGS AND THEIR USE AS THERAPEUTIC AGENTS AND DIAGNOSTIC PROBES UNIVERSITY OF BASEL (CH) 2011-11-10 US disclosed
EP-2364302-A2 TRIAZINE, PYRIMIDINE AND PYRIDINE ANALOGS AND THEIR USE AS THERAPEUTIC AGENTS AND DIAGNOSTIC PROBES University of Basel (CH) 2011-09-14 EP disclosed
WO-2010052569-A2 TRIAZINE, PYRIMIDINE AND PYRIDINE ANALOGS AND THEIR USE AS THERAPEUTIC AGENTS AND DIAGNOSTIC PROBES UNIVERSITY OF BASEL (CH) 2010-05-14 WO disclosed
WO-2010052569-A2 TRIAZINE, PYRIMIDINE AND PYRIDINE ANALOGS AND THEIR USE AS THERAPEUTIC AGENTS AND DIAGNOSTIC PROBES UNIVERSITY OF BASEL (CH) 2010-05-14 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110275762-A1 TRIAZINE, PYRIMIDINE AND PYRIDINE ANALOGS AND THEIR USE AS THERAPEUTIC AGENTS AND DIAGNOSTIC PROBES MTOR, PIK3CA, PIK3CD MAOA 2748/4885MAOB 1912/4885JAK2 177/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.